Scholarlink

<p>Urological malignancies impose a substantial global health burden, underscoring the urgent need for more effective therapeutic strategies. Although immunotherapy has transformed cancer management, its benefit in urological tumors remains inconsistent, often limited by tumor-intrinsic resistance and an immunosuppressive tumor microenvironment. In this setting, nanomedicine has emerged as a promising platform that extends beyond conventional drug delivery to actively modulate antitumor immune responses through engineered nano-bio interactions. This review presents a mechanistically organized overview of nanomedicine-enabled immunotherapeutic strategies for urological cancers, focusing on prostate cancer, renal cell carcinoma, and bladder cancer. We examine how advanced nanoplatforms regulate antitumor immunity through targeted delivery, externally activatable photodynamic immunotherapy, tumor immune microenvironment reprogramming, immunotherapy sensitization and combination strategies, and neoantigen–based vaccination. We also discuss key translational barriers—including delivery heterogeneity, biosafety, manufacturing scalability, and patient stratification—and outline design considerations for developing clinically translatable nano-based immunotherapeutic. Overall, this review highlights the potential of nanomedicine to overcome current limitations in cancer immunotherapy and to support the development of more effective, personalized treatments for urological malignancies.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanomedicine in immunotherapy of urinary system tumors: advances, synergistic strategies, and translational challenges

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月7日

查看全文
  • Wenpeng Huang,
  • Ayushi Chaudhary,
  • Zhaonan Sun,
  • Cynthia S. Reuben,
  • Sanjita Balaji,
  • Amanda R. Catey,
  • Song Luo,
  • Weibo Cai,
  • Jessica C. Hsu,
  • Jian Xu

摘要

Urological malignancies impose a substantial global health burden, underscoring the urgent need for more effective therapeutic strategies. Although immunotherapy has transformed cancer management, its benefit in urological tumors remains inconsistent, often limited by tumor-intrinsic resistance and an immunosuppressive tumor microenvironment. In this setting, nanomedicine has emerged as a promising platform that extends beyond conventional drug delivery to actively modulate antitumor immune responses through engineered nano-bio interactions. This review presents a mechanistically organized overview of nanomedicine-enabled immunotherapeutic strategies for urological cancers, focusing on prostate cancer, renal cell carcinoma, and bladder cancer. We examine how advanced nanoplatforms regulate antitumor immunity through targeted delivery, externally activatable photodynamic immunotherapy, tumor immune microenvironment reprogramming, immunotherapy sensitization and combination strategies, and neoantigen–based vaccination. We also discuss key translational barriers—including delivery heterogeneity, biosafety, manufacturing scalability, and patient stratification—and outline design considerations for developing clinically translatable nano-based immunotherapeutic. Overall, this review highlights the potential of nanomedicine to overcome current limitations in cancer immunotherapy and to support the development of more effective, personalized treatments for urological malignancies.

Graphical abstract